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Abstract Human prion diseases can be sporadic, inherited
or acquired by infection and show considerable phenotypic
heterogeneity. We describe the clinical, histopathological
and pathological prion protein (PrP
Sc) characteristics of a
Dutch family with a novel 7-octapeptide repeat insertion
(7-OPRI) in PRNP, the gene encoding the prion protein
(PrP). Clinical features were available in four, neuropatho-
logical features in three and biochemical characteristics in
two members of this family. The clinical phenotype was
characterized by slowly progressive cognitive decline,
personality change, lethargy, depression with anxiety and
panic attacks, apraxia and a hypokinetic-rigid syndrome.
Neuropathological ﬁndings consisted of numerous multi-
and unicentric amyloid plaques throughout the cerebrum
and cerebellum with varying degrees of spongiform
degeneration. Genetic and molecular studies were per-
formed in two male family members. One of them was
homozygous for valine and the other heterozygous for
methionine and valine at codon 129 of PRNP. Sequence
analysis identiﬁed a novel 168 bp insertion [R2–R2–R2–
R2–R3g–R2–R2] in the octapeptide repeat region of PRNP.
Both patients carried the mutation on the allele with valine
at codon 129. Western blot analysis showed type 1 PrP
Sc
in both patients and detected a smaller *8 kDa PrP
Sc
fragment in the cerebellum in one patient. The features of
this Dutch kindred deﬁne an unusual neuropathological
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DOI 10.1007/s00401-010-0656-3phenotype and a novel PRNP haplotype among the previ-
ously documented 7-OPRI mutations, further expanding
the spectrum of genotype–phenotype correlations in
inherited prion diseases.
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Introduction
Prion diseases, also known as transmissible spongiform
encephalopathies, are invariably fatal, neurodegenerative
disorders that can be sporadic, inherited or acquired by
infection.Theycanaffectbothhumansandawidevarietyof
animals, such as cattle, sheep and elk [24]. In humans,
inherited prion diseases include familial Creutzfeldt–Jakob
disease (CJD), Gerstmann–Stra ¨ussler–Scheinker (GSS)
disease and fatal familial insomnia (FFI) [6]. The clinical
phenotype in classical GSS disease is characterized by a
progressive cerebellar syndrome, accompanied by extrapy-
ramidal and pyramidal signs and cognitive decline, which
may evolve into severe dementia [8]. Neuropathological
features associated with GSS disease vary substantially, but
always include multicentric amyloid plaques in the cere-
bellum with or without spongiform change.
The central event in prion diseases is thought to be the
conversion of the normal prion protein (PrP
C) into the
pathological isoform, commonly referred to as PrP
Sc [24].
This process involves a structural rearrangement that
results in an increase in b-sheet content, aggregation and
partial resistance to proteolytic degradation. The physico-
chemical properties of PrP
Sc can be assessed indirectly by
determining the size of the protease-resistant core fragment
by Western blotting of proteinase-K (PK) digested
homogenates of brain tissue. Abnormal prion protein
deposits in affected brain regions of patients with CJD
include both full length PrP
Sc and truncated fragments in
the 12–21 kDa range, whereas in GSS disease smaller
protease-resistant 7–9 kDa unglycosylated fragments are
found [8, 21, 22].
About 10 point mutations in the protein encoding region
ofthe prion proteingene (PRNP)are knowntobe associated
with GSS disease. These are inherited in an autosomal
dominant manner and include both missense and nonsense
mutations, leading to amino-acid substitutions or a pre-
mature stop codon, respectively [8]. In addition, several
insertional mutations have been described that occur in the
N-terminal octapeptide repeat region of PRNP [14]. The
wild-type PRNP octapeptide repeat region is located
between codons 51 and 91, and comprises a nonapeptide,
designated R1, followed by four copies of an octapeptide,
designatedR2,R3andR4(Table 1).Thenormalsequenceof
the entire octapeptide region is R1–R2–R2–R3–R4 [9].
Octapeptide repeat insertions (OPRI) comprise varying
numbers (1–9) of 24 base pair multiples. If all insertional
mutations are considered together, the disease phenotype is
highlyvariable,oftenblendingfeaturesofbothCJDandGSS
disease or even lacking speciﬁc histopathological changes.
The molecular basis for this phenotypic heterogeneity
remains to be fully elucidated, but appears to depend in part
on the size of the base pair insertion and the codon 129
methionine/valine (M/V) polymorphism on the allele car-
rying the insertion [3, 18, 19].
An important step in clarifying phenotype–genotype
correlations is the description of new patients from well-
deﬁned kindreds and their comparison with previously
described kindreds. In this report, we describe the clinical,
neuropathological and biochemical ﬁndings in a Dutch
family with a novel seven octapeptide repeat insertional
mutation (7-OPRI) in PRNP.
Patients and methods
Patients
The pedigree of the kindred examined (Fig. 1) showed a
dementing illness in 6 subjects. Clinical details from
patients II-2, III-2, III-4 and III-6 were retrieved from
available hospital case records. The neuropathological
features of subjects III-2, III-4 and III-6 were re-analysed.
Additional genetic studies and immunoblotting of affected
brain tissue were performed in patients III-4 and III-6.
Table 1 Nucleotide sequences of codons 51–91 in normal, healthy indi-
viduals and irregular sequences in patients with insertional mutations in
PRNP
Normal (regular) sequences of codons 51–91 in PRNP
Codon 51
CCT CAG GGC GGT GGT GGC TGG GGG CAG R1
pro gln gly gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGG CAG R2
pro his gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGG CAG R2
pro his gly gly gly trp gly gln
CCC CAT GGT GGT GGC TGG GGA CAG R3
pro his gly gly gly trp gly gln
CCT CAT GGT GGT GGC TGG GGT CAA R4
pro his gly gly gly trp gly gln
Codon 91
Abnormal (irregular) sequence in affected individuals in this report
CCC CAT GGT GGT GGC TGG GGG CAG R3g
pro his gly gly gly trp gly gln
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The patient presented in 1962 with forgetfulness, apathy
and slurred non-ﬂuent speech at the age of 50 years. She
was also emotionally labile and developed anxiety attacks.
Her medical history was otherwise unremarkable. There
was no known history of iatrogenic prion exposure. On
neurological examination, she had a staring gaze and was
no longer able to communicate. The extremities were
spastic, but tendon and plantar reﬂexes were normal.
Routine blood tests were normal. A pneumo-encephalo-
gram showed severe atrophy and a slightly enlarged
ventricular system. An electroencephalogram (EEG) was
not recorded. Her condition deteriorated rapidly, compli-
cated by pulmonary infections. She died at the age of
50 years, 8 months after onset of symptoms. She had a
family history of neurodegenerative disease. Her mother
(I-2) had died at the age of 67 years, shortly after pre-
senting with similar symptoms. Two of the patient’s sisters
(II-4 and II-5) had died at the age of 47 and 49 years as a
result of an unknown neurological syndrome.
Subject III-2
This patient presented with decreasing driving abilities at
the age of 49 years, followed by an inability to complete
simple daily tasks, such as dressing. Eleven months later,
his family noted that he had become increasingly lethargic.
On examination in 1986, 12 months after onset of symp-
toms, he was unable to write, draw and read with explicit
disorders in memory, orientation, planning and judgement.
Movements were generally hypokinetic with rigidity in all
extremities. No myoclonic jerks were seen. The plantar
responses were extensor. Routine blood tests were normal.
An EEG showed non-speciﬁc changes, but no periodic
synchronous wave complexes (PSWC’s). His condition
deteriorated thereafter and 12 months later he had become
fully dependent on help with daily activities and was dis-
oriented in time and place. He died at the age of 51 years,
36 months after onset of symptoms.
Subject III-4
The patient, brother of subject III-2, presented with pro-
gressive gait insecurity, tinnitus and speech disability in
2003 at the age of 59 years. On examination, 1 month after
onset of symptoms, he was dysarthric with mild expressive
aphasia and saccadic eye movements. He had a mild
symmetric action tremor and showed an increased tone of
the extremities. The plantar responses were extensor.
Three months later his condition had deteriorated and was
characterized by a hypokinetic rigid syndrome. Neuro-
psychological evaluation revealed global aphasia, apraxia,
apathy and memory impairment. An EEG showed slowing
of background activity with PSWC’s. Magnetic resonance
imaging (MRI) showed mild symmetric hyperintense
lesions in the basal ganglia, but no atrophy. The last
3 months he became increasingly bedridden and developed
myoclonic jerks. He died at the age of 59 years, 7 months
after onset of symptoms.
Subject III-6
The patient, brother of III-2 and III-4, presented at the age
of 51 years with balance insecurity, forgetfulness, depres-
sion and panic attacks. He suffered from tinnitus and
sometimes noted numbness in ﬁngers and toes. On exam-
ination, 12 months after onset of symptoms, he was mildly
dysarthric and hypokinetic and showed increased tone of
all extremities. Tendon reﬂexes were brisk, but plantar
responses were extensor. Neuropsychological examination
revealed decreased concentration and impaired memory.
An EEG showed slowing of background activity, but no
PSWC’s. Over the next 3 years depression and panic
attacks continued, which improved with the use of anti-
depressive medication. On re-examination, ﬁve years after
onset of symptoms, his condition had suddenly deteriorated
with increasing bradyphrenia, hypokinetic rigidity, apraxia
and myoclonic jerks. In addition, he suffered from visual
hallucinations. Tendon reﬂexes were normal. MRI showed
cerebral atrophy, but no hyperintense lesions in the basal
ganglia. The ﬁnal stages of his disease course resembled
the rapid neurodegenerative decline of his family members.
He died at the age of 57 years, 65 months after onset of
symptoms.
Fig. 1 Pedigree of the family described in this manuscript. Circles
indicate females; squares correspond to males. Affected family
members are shown in shaded symbols, unaffected individuals in
open symbols.Adiagonal bar in a symbol indicates a deceased family
member. The question mark indicates a clinical history suggestive of
prion disease, albeit not neuropathologically proven. The numbers
refer to the case numbers in the text
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DNA was extracted from brain tissue of patients III-4 and
III-6. Full sequence analysis of the prion protein gene was
performed using established methods [13]. In addition the
genotype (methionine/valine) at the polymorphic codon
129 of PRNP was determined by restriction fragment
length analysis.
Neuropathology
Histopathological examination was performed on 5-lm
thick sections of formalin-ﬁxed and parafﬁn-embedded
brain tissue blocks, after decontamination for 1 h in
concentrated formic acid. Sections were stained with
haematoxylin–eosin and combined Luxol-periodic acid-
Schiff (PAS) stains according to standard procedures.
Congo red stains were performed on sections from tissues
untreated with formic acid. The monoclonal antibody 3F4
(1:400, overnight at 4C, Signet Laboratories, Dedham,
MA, USA) was used for PrP immunohistochemistry.
Pretreatment protocols for PrP staining involved antigen
retrieval by autoclaving in citric acid buffer pH 6.0 at
121C for 10 min followed by incubation with Proteinase
K (10 lg/mL, for 5 min at room temperature). Other
immunohistochemical stains included antibodies against
Ab (Ab1–17, 1:400, Dako, Glostrup, Denmark), phos-
phorylated tau (AT8 1:250, Innogenetics, Gent, Belgium),
Glial Fibrillary Acidic Protein (GFAP, 1:800, Dako,
Glostrup, Denmark), HLA-DRa (1:80, Dako, Glostrup,
Denmark) and ubiquitin (1:500, Dako, Glostrup,
Denmark).
Western blotting
Frozen tissues from the temporal, occipital and cerebellar
cortices (patient III-4 and III-6) were homogenized and
analysed for the presence and type of protease-resistant
PrP
Sc by Western blotting, using an established method
with minor modiﬁcations [12]. The homogenates were
immunoblotted with mAb 3F4 (1:1000, Dako, UK). The
isoform of PrP
Sc was classiﬁed as type 1 (unglycosylated
PrP
res of Mr * 21 kD) or type 2 (unglycosylated PrP
res
of Mr * 19 kD) based on the classiﬁcation system by
Parchi et al. [23]. Samples from both patients were run
alongside brain homogenates from sporadic and variant
Creutzfeldt–Jakob disease, a case of GSS (P102L-129M)
and a case of protease sensitive prionopathy [11] for
comparison of the relative mobility of the smaller frag-
ment sizes. PrP
res glycoform ratios were analysed using
densitometry using a GS-800 scanning densitometer
(Bio-Rad, UK).
Results
Genetic analysis
Patient III-4 was found to be heterozygous for methionine
and valine at codon 129 of PRNP, whereas patient III-6
was homozygous for valine. Ampliﬁcation of the octa-
peptide repeat region of the PRNP by PCR resulted in two
fragments, one of which was larger than the expected size,
suggesting the presence of an insertional mutation in one
of the PRNP alleles. Sequencing of this PCR product
demonstrated a 168-bp insertion in the octapeptide
repeat region [R2–R2–R2–R2–R3g–R2–R2] (Table 1).
Both patients carried the mutation on the codon 129 valine
allele.
Neuropathology
Gross examination of the brain of patient II-2 (weight
970 g) showed severe atrophy with frontal predominance.
The autopsy report mentioned extensive spongiform
changes in the cortex, accompanied by gliosis and neuronal
loss, consistent with prion disease. The presence of plaques
was not reported. Unfortunately, neither the slides nor the
tissue blocks could be retrieved for this study.
Gross examination of the brains of subjects III-2 (weight
unknown), III-4 (weight 1,295 g) and III-6 (weight
1,235 g) showed mild atrophy of the cerebellar cortex. The
results of microscopic examination (subjects III-4 and III-
6) are summarized in Table 2. Microscopic examination
revealed variable spongiform degeneration, astrocytic gli-
osis and neuronal loss in all areas of the cerebral cortex
(Fig. 2a, b), basal ganglia (Fig. 2e, f) and thalamus. The
cerebellum was also affected to a variable degree, char-
acterized by mild to moderate spongiosis of the molecular
layer (Fig. 2g, h). Furthermore, many PrP
Sc-positive and
congophilic multicentric and unicentric plaques were
present (Fig. 2c, d, j, k). These showed characteristic green
birefringence under polarized light, conﬁrming the pres-
ence of amyloid. The plaques were most numerous in the
molecular layer of the cerebellar cortex (Fig. 2j, k), but
were also found in large numbers in the cerebral cortex,
basal ganglia, thalamus and hippocampus. On higher
magniﬁcation, many plaques seemed to consist of smaller
eosinophilic globules, resembling the deposits reported in
an individual with a 144 bp insertion [7]. Elongated cere-
bellar deposits of PrP
Sc with perpendicular orientation to
the meningeal outline were not seen. The brainstem and
hippocampus were relatively spared. The spongiform
degeneration was more severe in the brain of patient III-6,
whereas the brain of patient III-4 showed less spongiosis,
but more amyloid plaques. Immunohistochemical staining
with anti-PrP antibodies showed positive staining of all
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in all cortical areas, basal ganglia, thalamus and the
molecular layer of the cerebellum. Fine ubiquitin deposits
were observed around some of the plaques, accompanied
by increased numbers of microglia in the HLA-DRa stain.
There were moderate numbers of diffuse plaques and few
cored Ab plaques in the frontal cortex, but less in other
cortical areas. Neuritic plaques were not seen. Immuno-
histochemical staining with AT8 showed diffuse punctuate
staining with sparse neuropil threads in all areas examined,
including the striatum and molecular layer of the cerebel-
lum. In addition, few neuroﬁbrillary tangles were focally
noted in the hippocampus, frontal cortex and temporal
cortex of subject III-6, whereas they were absent in subject
III-4. Together, these changes were regarded as Alzheimer
changes, corresponding to Braak stage 1B. Microscopic
examination of the remaining regions of the brain was
unremarkable.
Western blotting
Western blot analysis of protease-resistant prion protein
(PrP
res) in brain homogenates of patients III-4 and III-6
demonstrated the presence of type 1 PrP
res. In addition,
patient III-4 had a smaller PrP
res fragment seen consis-
tently, but only in the cerebellar specimen (Fig. 3a).
Densitometric analysis of the 20–30 kDa PrP
res bands
showed a glycoform ratio similar to that found in sporadic
CJD, being dominated by the monoglycosylated (middle)
band seen on Western blots, however this pattern was
found to be modiﬁed towards over-representation of non-
glycosylated forms in the cerebellar specimen from patient
III-4, in which the small fragment was also evident
(Fig. 3b). Comparison of the cerebellar specimen from
patient III-4 with samples from other prion diseases in
which low-molecular weight PrP
res fragments are also
found, showed that the PrP
res fragment in this 7-OPRI case
was of the same general mobility as the major low-
molecular weight fragments found in cases of GSS and
PSPr (Fig. 3c).
Analysis of combined data
Clinical and neuropathological features in this Dutch kin-
dred may be combined with those of other families and
patients with 7-OPRI (Table 3). Marked phenotypic het-
erogeneity is a consistent feature in these reports. Age at
onset was known for four patients in our family, ranging
from 49 to 59 years (mean 52.2 years, SD = 4.6 years).
The disease duration ranged from 0.6 to 5.4 years (mean
2.4 years; SD = 2.3 years). In contrast, the age at onset
was known in 9 previously reported patients, carrying
similar 7-OPRI, ranging from 18 to 44 years (mean
28.9 years; SD = 7.3 years). The disease duration in these
patients ranged from 4 to 16 years (mean 10.3 years;
SD = 3.4). Whereas the insertional mutation in our patient
was coupled to valine on codon 129 of PRNP, it occurred
on a methionine background in all previously reported
patients. Therefore, haplotype deﬁned by direct physical
linkage of the insertion to valine at position 129 appears to
be associated with later age at disease onset (independent
samples t test with assumption of equal variances, mean
difference 23.4 years, p\0.001) and shorter disease
duration (independent samples t test with assumption of
equal variances, mean difference 7.9 years, p = 0.001). It
is also noteworthy that of the two siblings (III-4 and III-6),
the patient with valine at codon 129 of the wild-type allele
(in addition to valine linked to the mutation) had an earlier
onset and a substantially longer disease duration. There-
fore, PRNP codon 129 appears to exert a modifying effect
on the age at onset and disease duration in 7-OPRI,
although these ﬁndings must be interpreted with caution,
being limited to single cases only. A similar modifying
effect of codon 129 on age at onset was seen in 5-OPRI and
Table 2 Regional distribution of spongiosis, neuronal loss/gliosis and multicentric plaque density
FC PC TC OC Hipp STR Th BRST CE
III-4
Spongiosis ?? ? ? ?? - ?? ? - ?
Gliosis/neuronal loss ?? ? ?? ?? ? ?? ? - -
Multicentric plaques ?? ? ? ?? ? ??? ? - ???
III-6
Spongiosis ??? ?? ?? ?? ? ?? ?? -/?? ?
Gliosis/neuronal loss ?? ?? ?? ?? ? ?? ?? -/?? ?
Multicentric plaques ? ???? ? ?- ? ?
Each lesion was scored semi-quantitatively as not detectable (-), mild (?), moderate (??) and severe (???). The number of PrP-positive
multicentric plaques were counted per HPF and scored as not detectable (-), 1–4 plaques (?), 5–9 plaques (??) and 10–15 plaques (???)
FC frontal cortex, PC parietal cortex, TC temporal cortex, OC occipital cortex, Hipp hippocampal formation, STR striatum, Th thalamus, BRST
brainstem, CE cerebellum
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123Fig. 2 Histopathological
ﬁndings in two family members
(III-4 and III-6) with 7-OPRI.
Sections are stained with
haematoxylin–eosin (a, b, e, f,
g and h) and the 3F4 anti-PrP
antibody (c, d, j and k), original
magniﬁcation 9200. Mild (a)
and severe (b) spongiform
change in the frontal cortex;
c, d multicentric and unicentric
plaques in the frontal cortex;
e mild spongiform change with
multicentric plaques (arrows)i n
the caudate nucleus; f severe
spongiform change in the
caudate nucleus; g, j many
multicentric plaques in the
molecular layer of the
cerebellum; h, k moderate
spongiform change with
multicentric plaques (arrow)i n
the molecular layer of the
cerebellum
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1236-OPRI cases [18, 19], although there was no effect on
disease duration.
Discussion
In this report, we describe a Dutch family with inherited
prion disease and a novel 7-octapeptide-repeat-insertion
(7-OPRI).Thiskindredrepresentsthesixthreportedpedigree
to harbour a 7-OPRI in PRNP. In our family, the 7-OPRI is
carried on the valine allele of codon 129 of PRNP, and the
sequenceandarrangementofthe168 bpinsertiondiffersfrom
those previously described in the literature. In all 10 patients
with 7-OPRI reported in the literature so far, the mutation
was located on the methionine allele of codon 129 of PRNP
[1,2,4,9,10,16,17,25,27].Themedianageatonsetinthese
patients was 28.9 years (range 18–44 years) and the median
disease duration 10.0 years (range 4–16 years). Histopathol-
ogical features usually comprise varying degrees of
spongiosis,neuronallossandgliosiswithcharacteristiclinear
deposits of PrP in the cerebellar cortex in two patients [4].
Interestingly, no amyloid plaques were reported. In contrast,
the clinical phenotype in our patients was characterized by a
relatively late age at onset (mean 52.3 years; range 49–
59 years), progressive cognitive decline, extrapyramidal
symptoms, psychiatric disorders and a mean disease duration
of 2.4 years (range 0.6–5.4 years). Neuropathological ﬁnd-
ings included many multicentric plaques, consistent with a
GSS-like phenotype, with moderate to severe spongiosis,
neuronalloss and gliosis.Althoughit istempting to relatethe
shorterdiseasedurationobservedinthisfamilytothepresence
ofvalineatcodon129inthemutatedPRNPallele,thereisalso
a strong effect of age on disease duration in inherited prion
diseases (i.e. longer disease duration being associated with
younger age at onset), which may confound the comparison.
Interestingly, the two patients in this family with the longer
disease duration showed more severe spongiform change,
whereas a shorter disease duration seemed to be associated
with more abundant multicentric amyloid plaques and less
severe spongiform change. This observation is unexpected,
since among the known prion protein amyloidoses, the num-
ber of amyloid plaques usually increases with longer disease
duration. At the moment, we do not have a suitable explana-
tion for this apparent discrepancy, although the PRNP codon
129 polymorphism in the non-mutated allele appears to have
playedarolesincethepresenceofvalineatcodon129inboth
thewild-typeandmutantalleleswasassociatedwithanearlier
age at onset, a longerdisease duration, more spongiosis and a
lower number of amyloid plaques. Of course, the interpreta-
tion of these ﬁndings should be performed with caution
because of the limited number of cases.
Thefunctionalsigniﬁcanceoftheoctapeptiderepeatregion
inPRNP stillremainscontroversial, althoughitwas shownto
bind copper and may play a role in neuroprotective function
[20]. It may also be related to amyloid formation, as patients
with 8 or9 extra repeats often showa GSS disease phenotype
with numerous multicentric plaques [5, 9, 15, 26], whereas
patients with OPRI mutations consisting of less than 5 extra
repeats present in a way similar to the typical presentation of
CJD. Nevertheless, the exact mechanism of amyloid forma-
tion in prion diseases still remains to be elucidated. Data
obtained from the study of puriﬁed amyloid fractions in
patients with several forms of GSS disease indicate that the
minimalPrP
ScsegmentessentialforamyloidogenesisisanN-
and C-terminally truncated fragment spanning residues 88–
146 [8]. This corresponds to the 7–9 kDa unglycosylated
fragments typically seen on Western blotting. Interestingly,
one ofour patientsshoweda similar *8-kDa fragment inthe
Fig. 3 Western blot analysis of two family members (III-4 and III-6)
with 7-OPRI. In a protease-resistant prion protein (PrP
res) from
specimens of temporal cortex (TC) and cerebellum (Cb) from one
patient (III-4) and from specimens of temporal cortex (TC) and
occipital cortex (OC) from the other patient (III-6) are shown ﬂanked
by reference standards of frontal cortex from sporadic CJD of the
MM1 subtype (1) and frontal cortex from variant CJD (2B). In b the
relative abundance of the three different glycoforms of PrP
res is
shown, calculated on the basis of densitometric analysis of three
independent samples from the available frozen tissues shown in a.
The relative abundance of the upper (diglycosylated) band is shown in
black, the middle (monoglycosylated) band is shown in grey and the
lower (non-glycosylated) band is shown in white.I nc the PrP
res
proﬁle from the cerebellum in patient III-4 (III-4 Cb) is compared
with those found in a patient with Gerstmann–Stra ¨ussler–Scheinker
disease carrying a proline to leucine substitution at position 102 (GSS
P102L), and samples from the temporal cortex and occipital cortex of
a Dutch case of protease sensitive prionopathy (PSPr TC and PSPr
OC). M denotes molecular weight markers with their Mr indicated in
kDa. The loading of individual samples on Western blots (volume of
10% weight/volume brain homogenate) was adjusted to allow easy
comparison of the PrP
res proﬁles obtained. All densitometric readings
for glycoform analysis were within the linear range for each band in
every sample
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123cerebellum.Anotherinterestingﬁndingwasthesimultaneous
presence of 20–30 kDa PrP
Sc fragments, corresponding to
type 1 PrP
Sc.T h i sP r P
Sc isoform was originally described in
individualswithsCJD,whichischaracterizedbythepresence
of spongiform degeneration [22]. Therefore, the presence of
both type 1 PrP
Sc isoforms and smaller fragments of PrP may
account for the neuropathological phenotype seen in our
patients, consisting of spongiform degeneration and the
presence of amyloid plaques. Smaller fragments were not
described in two other cases with 7-OPRI reported in the lit-
erature [16,27],whichis quiteinagreement withthe factthat
they lacked amyloid plaques. It is not exactly clear what
caused the failure to detect smaller PrP fragments in our
secondpatient(III-6),butthe(differencein)size,qualityand/
or precise origin of the frozen specimens taken at autopsy for
further molecular analysis might have contributed to this
failure. In addition, the lower amyloid burden in this patient
may have played a role as well.
The 7-OPRI mutation in this pedigree was inherited in
an autosomal dominant pattern. However, it is important to
note that a negative family history does not exclude the
possibility of inherited prion disease, exempliﬁed by a
recently reported Italian patient with a de novo 7-OPRI [2,
17]. Although genetic cases of prion disease may be
identiﬁed well on the basis of a positive family history or
unusual clinical and neuropathological features alone, pre-
mortem PRNP sequencing should be considered in all
patients with a clinical history of atypical dementia.
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